Marc Auriacombe, MD

Team Leader and Medical Director
University of Bordeaux and CH Charles Perrens

Dr. Auriacombe works in a group that started using opiate agonist maintenance treatments for heroin addiction in the mid-80s with Dr. Daulouède and Pr. Tignol and is among those that have the largest clinical experience with opiate agonist treatments in France. Dr. Auriacombe is the principal senior investigator of an integrated addiction research program funded by French national and European funds and has published over 200 papers addressing the commonalities across addictive behaviors. In an academic field pervaded by dogmatism, polarization and resistance to new concepts, Dr. Auriacombe is a notable exception. Both in depth and in breadth, his academic and scientific contributions are extraordinary. He has conceived, designed and carried out research investigations of major importance, particularly on craving, individualized precursors to relapse, and related comorbidities in the drug use disordered population. Dr. Auriacombe’s work demonstrates an indispensable persistence and courage in the quest for new and improved therapeutic approaches for opioid use disorders.

AATOD is delighted to share the article Mark Parrino (AATOD President) wrote for the Addiction Professional and Behavioral Healthcare Executive, which was released earlier today.
Link to Article ➡️
https://bit.ly/3KgGpWs

Load More...

#aatod2022 conference

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram

Stay Connected to AATOD